Short Summary
Samsung and SiOnyx reached a settlement that terminated the inter partes review of U.S. Patent 10,224,359 before the trial was instituted. The Board ordered the settlement and related license agreement to be kept confidential.
Detailed Summary
In IPR2025-00162, Samsung Electronics and patent owner SiOnyx filed a joint motion to terminate the inter partes review of U.S. Patent 10,224,359 B2 after reaching a settlement agreement, which also involved a license with RPX Corporation. The Patent Trial and Appeal Board determined that the parties satisfied the statutory requirements for termination under 35 U.S.C. §317(b) and 37 C.F.R. §42.74, granting the motion and ordering the settlement documents to be treated as business‑confidential information. The proceeding was thus terminated prior to institution, and the related patents were removed from the Board’s public docket.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in Samsung Electronics Co., Ltd. et al. vs SiOnyx, LLC is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Samsung Electronics Co., Ltd. et al.vsOura Health Oy et al.
The PTAB denied institution of an IPR filed by Samsung against Oura Health because the patent owner had formally disclaimed all 12 challenged claims.
Tableau Software, LLC et al.vsiCharts LLC
Tableau Software has filed a request for Director Review to overturn the PTAB’s denial of institution of an IPR against its interactive‑chart patent. The petition contends the Board erred on claim constructions, the disclosure of a second website, and motivation to combine prior art references.
Samsung Electronics Co., Ltd. et al.vsST CasesTech, LLC et al.
Samsung and Staton Techiya have settled their dispute over U.S. Patent 11,683,643, filing a joint motion to terminate the inter partes review. The Board is asked to end the proceeding under 35 U.S.C. §317(a).
Abbott Laboratories et al.vsMIRACOR MEDICAL SA
The PTAB denied Director Review requests for three IPR institution decisions, including IPR2025-00115 concerning patent 11,674,517 owned by Miracor Medical and challenged by Abbott Laboratories. The institution decisions therefore remain in effect.
HARMAN INTERNATIONAL INDUSTRIES, INC.vsST CasesTech, LLC et al.
Harman and CasesTech settled their IPR dispute before trial, leading the Board to terminate the proceeding and treat the settlement agreement as confidential.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.